Keywords
Malassezia
pityriasis versicolor
fungal infection
How to Cite
Abstract
This study evaluated the sensitivity of Malassezia spp. strains, the etiologic agent of pityriasis versicolor, to essential oil from Cymbopogon citratus. The chemical composition of the essential oil was analysed by GC-MS, and the major constituents were: geraniol (52.80%), neral (36.65%) and myrcene (3.73%). The minimum inhibitory concentration (MIC) of C. citratus essential oil on to 22 strains of Malassezia spp. were determined by agar dilution technique in the presence and absence of ergosterol (50-250 μg/mL) and sorbitol (0.8 M). Increased MIC values in the presence of ergosterol indicate an effect on fungal membrane, and the higher MIC values in the presence of sorbitol indicate a mechanism of action on the cell wall. The MIC ranged from 0.31 to 1.25 μL/mL and it increased fourfold in the presence of ergosterol, regardless of concentration tested; and this fact was most likely related to the occurrence of the oil and exogenous ergosterol complexes. No change in MIC values in the presence of sorbitol was found. These data infer that C. citratus essential oil causes an effect on Malassezia spp. plasma membrane synthesis by binding to ergosterol. This study contributes to the development of new antifungal drugs, especially against Malassezia spp.References
1. Quindos G. Las micosis en el amanecer del siglo XXI. Rev Iberoam Micol. 2002;19:1-4.
2. Tragiannidis A, Bisping G, Koehler G, Groll AH.Minireview: Malassezia infections in immunocompromised patients. Mycoses. 2009;53(3):187-95.
3. Batra R, Boekhout T, Gueho E, Cabañes FJ, Dawson TL, Gupta AK. Malassezia Baillon, emerging clinical yeasts. FEMS Yeast Res. 2005;5(12):1101-13.
4. Miranda KC, Araujo CR, Costa CR, Passos XS, Fatima LFO, Rosário RSM.Antifungal activities of azole agents against the Malassezia species. Int J Antimicrob Agents. 2007;29(3):281-4.
5. Ashbee HB. Update on the genus Malassezia. Med Mycol. 2007;45(4):287-303.
6. Baysal V, Yildirim M, Ozcanli C, Ceyhan AM.Itraconazole in the treatment of seborrheic dermatitis: a new treatment modality. Int J Dermatol. 2004;45(1):63-6.
7. Curtis L, Cali S, Conroy L, Baker K, Ou CH, Hershow R, et al. Aspergillus surveillance project at a large tertiary-care hospital. J Hosp Inf. 2005;59(3):188-96.
8. Barberán J, Mensa J, Fariñas C, Llinares P, Serrano S, Ménendez R, et al.Recommendations of antifungal treatment in patients with low grade inmunosuppression. Rev Esp Quimioter. 2008;21(2):127-42.
9. Odds FC, Brown AJP, Gow NAR. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11(6):272-9.
10. Cimanga K, Kambu K, Tona L, Apers S, De Bruyne T, Hermans N, et al. Correlation between chemical composition and antibacterial activity of essential oils of some aromatic medicinal plants growing in the Democratic Republic of Congo. J Ethanopharmacol. 2002;79(2):213-20.
11. Ferreira TM, Silva FS, Teodoro GR, Costa ACBP, Maria A, Beltrame Junior M, et al. Atividade antifúngica do citral em leveduras do gênero Candida isoladas de pacientes hospitalizados. Rev Inst Adolfo Lutz. 2009;68(1):118-25.
12. Nunes XP, Maia GLA, Almeida JRGS, Pereira FO, Lima EO.Antimicrobial activity of the essential oil of Sida cordifolia L. Braz J Pharmacogn. 2003;16:642-4.
13. Lima EO, Gompertz OF, Giesbrecht AM,Paulo MQ. In vitro antifungal activity of essential oils obtained from officinal plants against dermatophytes. Mycoses. 1993;36(9-10):333-6.
14. Silva FS, Ferreira TM, Teodoro GR, Costa ACBP, Maria A, Beltrame Junior M, et al.Antifungal activity of Cymbopogon citratus essential oil on Candida albicans and Candida tropicalisstrains isolated from nosocomial infections.Rev Inst Adolfo Lutz. 2009;68(3):434-41.
15. Irkin R, Korukluoglu M. Effectiveness of Cymbopogon citratus L. essential oil to inhibit the growth of some filamentous fungi and yeasts. J Med Food. 2009;12(1):193-7.
16. Naik MI, Fomda BA, Jaykumar E, Bhat JA.Antibacterial activity of lemongrass (Cymbopogon citratus) oil against some selected pathogenic bacterias. Asian Pacific J Trop Med. 2010;3(7):535-8.
17. Schuck VJA, Fratini M, Rauber CS, Henriques A, Schapoval EES.Avaliação da atividade antimicrobiana de Cymbopogon citratus. Braz J Pharm Sciences. 2001;37(1):45-9.
18. Adams RP. Identification of essential oils components by gas chromatography/quadrupole mass spectroscopy. Chicago: Allured Publishing Corporation; 2001.
19. Erchiga VC, Palomo MC, Moyano EG. Diagnóstico de laboratorio de lãs levaduras del gênero Malassezia. Piel. 2008;23(10):570-6.
20. Neufeld PM. Manual de micologia médica: técnicas básicas de diagnóstico. Rio de Janeiro: Programa Nacional de Controle de Qualidade; 1999.
21. Cleeland R, Squires E. Evalution of new antimicrobials “in vitro” and in experimental animal infections. In: LORIAN, V. M. D. Antibiotics in Laboratory Medicine. Willians & Wilkins; 1991:739-788.
22. Hadacek F, Greger H. Testing of antifungal natural products: methodologies, comparability of results and assay choice. Phyto Anal. 2000;11(3):137-47.
23. Allegrini J, Bouchberg MS, Maillols H. Émulsions d’huiles esentielles fabrication et applications en microbiologie. Soc Pharm Mont. 1973;33(1):73-86.
24. Santos FA, Bastos EMA, Uzeda M, Carvalho MAR, Farias LM, Moreira ESA.Antibacterial activity of propolis produced in Brazil against Actinobacillus acinomycetemcomitans, Fusobacterium spp. and bacteria from the Bacterioides fragilis group isolated from humam and marmoset hosts. Anaer. 1999;5:479-81.
25. Frost DL, Brandt KD, Cugier D, Goldman R. A whole-cell Candidaalbicans assay for the detection of inhibitors towards fungal cell wall synthesis and assembly. J Antib. 1995;48(4):306-10.
26. Svetaz L, Aguero MB, Alvarez S, Luna L, Feresin G, Derita M, et al.Antifungal activity of Zuccagnia punctata cav.: Evidence for the mechanism of action. Planta Med. 2007;73(10):1-7.
27. Escalante A, Gattuso M, Perez P, Zacchino S.Evidence for the mechanism of action of the antifungal phytolaccoside B isolated from Phytolacca tetrâmera Hauman. J Nat Prod. 2008;71(10):1720-5.
28. Silva Junior IF, Raimondi M, Zacchino M, Cechinal Filho V, Noldin VF, Rao VS, et al. Evaluation of the antifungal activity and mode of action of Lafoensia pacari A. St.-Hil., Lythraceae, stem-bark extracts, fractions and ellagic acid. Braz J Pharmacogn. 2010;20(3):422-8.
29. Kasali AA, Oyedeji AO, Ashilokun AO. Volatile leaf oil constituents of Cymbopogon citratus (DC) Stapf. Flav Frag J. 2001;16(5):377-8.
30. Andrade EHA, Zoghbi MGB, Lima MP. Chemical Composition of the Essential Oils of Cymbopogon citratus (DC.) Stapf Cultivated in North of Brazil. J Essential Oil Bear Plant. 2009;12(1):41-5.
31. Guerra MJM, Badell JB, Albajes ARR, Perez HB, Meneses RF, Lainez AA. Evaluación toxicológica aguda de los extractos fluidos al 30 y 80% de Cymbopogon citratus (D.C.) Stapf (Caña Santa). Rev Cubana Plant Med. 2000;5(3):97-101.
32. Onawunmi GO, Yisak WA, Ogunlana EO. Antibacterial constituents in the essential oil of Cymbopogon citratus (DC.) Stapf. J Ethnopharmacol. 1984;12(3):279-86.
33. Belém LF, Lima EO, Barbosa Filho JM, Silva Filho RN, Lima JR, Casimiro GS. Atividade antifúngica de óleos essenciais “in vitro” contra cepas de Malassezia furfur. Rev Bras Pl Med. 2003;6(1):77-83.
34. Pereira FO. Antifungal activity of the essential oil of Cymbopogon winterianus Jowitt ex Bor on dermatophytes of the genus Trichophyton [dissertação de mestrado]. João Pessoa, PB: Universidade Federal da Paraíba; 2009.
35. Valgus JM. What’s new in antifungals? Curr Infect Dis Rep. 2003;5(1):16-21.
36. Cihlar RL, Kellogg C, Broedel Junior S. Antifungal drugs targets: discovery and selection. In: Calderone RA, Cihlar RL.Fungal pathogenesis: principles and clinical applications. Nova York: Marcel Deckker; 2002.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2012 Instituto Adolfo Lutz Journal